PROTAGENIC THERAPEUTICS, INC. The trial, which included 30 subjects across five cohorts receiving doses up to 1,000 micrograms, reported zero clinically-relevant adverse events.
PT00114 targets stress reduction, which is increasingly recognized as the root cause of major psychiatric disorders, including PTSD, depression, anxiety, and addiction. Emerging evidence also suggests that stress may be a significant contributor to obesity. By addressing the stress-chemical cascade, PT00114 has the potential to offer a novel approach to treating these conditions.
'The exceptional safety results from the single dose portion of the Phase I trial are highly encouraging,' commented Dr.
The company will hold an interactive investor call today,
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 740983 and join at least five minutes before the scheduled start time.
About PT00114
PT00114 is a candidate to become a therapeutic for severe neuropsychiatric conditions, mimicking the naturally occurring brain peptide TCAP to counteract stress-induced hormonal effects.
Forward-Looking Statements
Statements in this release about future expectations are 'forward-looking' and subject to risks and uncertainties. Investors are cautioned against placing undue reliance on such statements.
Contact:
Tel: 213-260-4342
Email: alex.arrow@protagenic.com
Tel: 646-823-8656
Email: ksmith@pcgadvisory.com
(C) 2024 Electronic News Publishing, source
